Sunesis Pharmaceuticals, Inc.
Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies whose disease has progressed after prior therapies. The Phase 1b identifies the recommended dose of vecabrutinib and the Phase 2 will further characterize the safety and activity of vecabrutininb in CLL patients. Beyond the development of vecabrutinib, the company has other kinase inhibitor programs, including Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which has broad applicability across hematologic and solid cancers.